Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma.
Investigating the relative efficacies of combination chemotherapy of paclitaxel/carboplatin, with or without anthracycline, for endometrial carcinoma.
复制标题
DOI：
10.1007/s00404-011-2154-9
复制
发表时间：
2012-05
影响因子：
2.6
通讯作者：
Kimura T
中科院分区：
文献类型：
--
作者：
Fujiwara K;Egawa-Takata T;Ueda Y;Kimura T;Yoshino K;Fujita M;Miyatake T;Ohta Y;Kamiura S;Enomoto T;Kimura T
最近，紫杉醇和卡铂（TC）（不含蒽环类药物）的组合已开始用作辅助或缓解诱导治疗，相对于紫杉烷、铂和蒽环类药物如TEC（紫杉醇、表阿霉素和卡铂）的组合化疗，没有任何关键的支持性证据证明其疗效。我们目前研究的目的是进行所需的临床评价的相对有效性TC相比，TEC。回顾性比较了1999年至2009年分别在大坂大学医院和日本大坂癌症和心血管疾病大坂医学中心使用TEC和TC方案治疗子宫内膜癌的疗效。接受TEC或TC治疗的患者的临床特征没有显著差异，并且TEC和TC治疗是基于相似的化疗适应症开始的。TEC方案为紫杉醇（150 mg/m2）、表阿霉素（50 mg/m2）和卡铂（AUC 4）。TC方案为紫杉醇（175 mg/m2）+卡铂（AUC 5）。TEC作为切除的III/IV期疾病的辅助治疗，其生存率明显优于TC（对数秩检验，无进展生存率p = 0.017，总生存率p = 0.014）。然而，在复发或更晚期的病例中，TC和TEC对生存期的影响相似（无进展生存期p = 0.55，总生存期p = 0.63）。TEC应作为III/IV期患者的辅助治疗提供。对于复发或不能切除的病例，可考虑TC作为缓解诱导治疗。
Recently a combination of paclitaxel and carboplatin (TC) (without an anthracycline) has begun to be used as an adjuvant or remission induction therapy, without any critical supportive evidence of its efficacy relative to a combination chemotherapy of taxane, platinum and anthracycline such as TEC (paclitaxel, epirubicin and carboplatin). The aim of our present study was to conduct the required clinical evaluations of the relative effectiveness of TC compared to TEC. A retrospective comparison between the efficacy of TEC and TC regimens used for endometrial carcinoma at the Osaka University Hospital and the Osaka Medical Center for Cancer and Cardiovascular Diseases in Osaka, Japan, respectively, from 1999 to 2009 was performed. The clinical characteristics of the patients who received either TEC or TC were not significantly different, and TEC and TC therapies were initiated based on similar indications for chemotherapy. TEC regimen was paclitaxel (150 mg/m2), epirubicin (50 mg/m2) and carboplatin (AUC 4). TC regimen consisted of paclitaxel (175 mg/m2) and carboplatin (AUC 5). TEC was demonstrated to provide significantly better survival than TC as an adjuvant therapy for resected Stage III/IV diseases (p = 0.017 for progression-free survival and p = 0.014 for overall survival, by the log-rank test). However, in recurrent or more advanced cases, TC and TEC demonstrated similar effects on survival (p = 0.55 for progression-free survival and p = 0.63 for overall survival). TEC should be offered as an adjuvant therapy to Stage III/IV patients. TC may be considered for recurrent or unresectable cases as a remission induction therapy.
登录
查看更多内容
影响因子：
10.3
作者：
du Bois, A;Lück, HJ;Pfisterer, J
通讯作者：
Pfisterer, J
影响因子：
4.7
作者：
Papadimitriou, Christos A.;Bafaloukos, Dimitrios;Dimopoulos, Meletios-A.
通讯作者：
Dimopoulos, Meletios-A.
影响因子：
9.7
作者：
Ueno, Yuko;Enomoto, Takayuki;Murata, Yuji
通讯作者：
Murata, Yuji
影响因子：
45.3
作者：
Fleming, GF;Brurietto, VL;Burks, RT
通讯作者：
Burks, RT
DOI：
10.1111/igc.0b013e3181ad3dcb
发表时间：
2009-08-01
影响因子：
4.8
作者：
Vandenput, Ingrid;Vergote, Ignace;Amant, Frederic
通讯作者：
Amant, Frederic